Global Cutaneous Leishmaniasis Drugs Market Size, Share, Trends and Forecast 2022-2030

Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.

Industry Insights

Due to the COVID-19 pandemic, the global Cutaneous Leishmaniasis Drugs market size is estimated to be worth US$ 43 million in 2021 and is forecast to a readjusted size of US$ 57 million by 2028 with a CAGR of 4.1% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Cutaneous Leishmaniasis Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Cutaneous Leishmaniasis Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.

This report focuses on Cutaneous Leishmaniasis Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Cutaneous Leishmaniasis Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and India, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Cutaneous Leishmaniasis Drugs market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Pentavalent Antimonials

Antifungal Drugs

Anti-Leishmanial/Antimicrobial Drugs

Segment by Application

Hospital

Retail Pharmacy

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

GSK

Novartis

Sanofi

Gilead Sciences

Bristol-Myers Squibb

Albert David

Profounda

Knight Therapeutics

Pfizer

Xinhua Pharma

1 Cutaneous Leishmaniasis Drugs Market Overview
1.1 Product Overview and Scope of Cutaneous Leishmaniasis Drugs

1.2 Cutaneous Leishmaniasis Drugs Segment by Type

1.2.1 Global Cutaneous Leishmaniasis Drugs Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Pentavalent Antimonials

1.2.3 Antifungal Drugs

1.2.4 Anti-Leishmanial/Antimicrobial Drugs

1.3 Cutaneous Leishmaniasis Drugs Segment by Application

1.3.1 Global Cutaneous Leishmaniasis Drugs Sales Comparison by Application: (2022-2028)

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Others

1.4 Global Cutaneous Leishmaniasis Drugs Market Size Estimates and Forecasts

1.4.1 Global Cutaneous Leishmaniasis Drugs Revenue 2017-2028

1.4.2 Global Cutaneous Leishmaniasis Drugs Sales 2017-2028

1.4.3 Cutaneous Leishmaniasis Drugs Market Size by Region: 2017 Versus 2021 Versus 2028

2 Cutaneous Leishmaniasis Drugs Market Competition by Manufacturers

2.1 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Manufacturers (2017-2022)

2.2 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Cutaneous Leishmaniasis Drugs Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Cutaneous Leishmaniasis Drugs Manufacturing Sites, Area Served, Product Type

2.5 Cutaneous Leishmaniasis Drugs Market Competitive Situation and Trends

2.5.1 Cutaneous Leishmaniasis Drugs Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Cutaneous Leishmaniasis Drugs Players Market Share by Revenue

2.5.3 Global Cutaneous Leishmaniasis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Cutaneous Leishmaniasis Drugs Retrospective Market Scenario by Region

3.1 Global Cutaneous Leishmaniasis Drugs Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Cutaneous Leishmaniasis Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country

3.3.1 North America Cutaneous Leishmaniasis Drugs Sales by Country

3.3.2 North America Cutaneous Leishmaniasis Drugs Revenue by Country

3.3.3 United States

3.3.4 Canada

3.4 Europe Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country

3.4.1 Europe Cutaneous Leishmaniasis Drugs Sales by Country

3.4.2 Europe Cutaneous Leishmaniasis Drugs Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Cutaneous Leishmaniasis Drugs Market Facts & Figures by Region

3.5.1 Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Region

3.5.2 Asia Pacific Cutaneous Leishmaniasis Drugs Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 China Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.6 Latin America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country

3.6.1 Latin America Cutaneous Leishmaniasis Drugs Sales by Country

3.6.2 Latin America Cutaneous Leishmaniasis Drugs Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.6.6 Colombia

3.7 Middle East and Africa Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country

3.7.1 Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country

3.7.2 Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Cutaneous Leishmaniasis Drugs Historic Market Analysis by Type

4.1 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2017-2022)

4.2 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2017-2022)

4.3 Global Cutaneous Leishmaniasis Drugs Price by Type (2017-2022)

5 Global Cutaneous Leishmaniasis Drugs Historic Market Analysis by Application

5.1 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2017-2022)

5.2 Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2017-2022)

5.3 Global Cutaneous Leishmaniasis Drugs Price by Application (2017-2022)

6 Key Companies Profiled

6.1 GSK

6.1.1 GSK Corporation Information

6.1.2 GSK Description and Business Overview

6.1.3 GSK Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.1.4 GSK Cutaneous Leishmaniasis Drugs Product Portfolio

6.1.5 GSK Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Corporation Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Novartis Cutaneous Leishmaniasis Drugs Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Sanofi

6.3.1 Sanofi Corporation Information

6.3.2 Sanofi Description and Business Overview

6.3.3 Sanofi Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Sanofi Cutaneous Leishmaniasis Drugs Product Portfolio

6.3.5 Sanofi Recent Developments/Updates

6.4 Gilead Sciences

6.4.1 Gilead Sciences Corporation Information

6.4.2 Gilead Sciences Description and Business Overview

6.4.3 Gilead Sciences Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Gilead Sciences Cutaneous Leishmaniasis Drugs Product Portfolio

6.4.5 Gilead Sciences Recent Developments/Updates

6.5 Bristol-Myers Squibb

6.5.1 Bristol-Myers Squibb Corporation Information

6.5.2 Bristol-Myers Squibb Description and Business Overview

6.5.3 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Product Portfolio

6.5.5 Bristol-Myers Squibb Recent Developments/Updates

6.6 Albert David

6.6.1 Albert David Corporation Information

6.6.2 Albert David Description and Business Overview

6.6.3 Albert David Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Albert David Cutaneous Leishmaniasis Drugs Product Portfolio

6.6.5 Albert David Recent Developments/Updates

6.7 Profounda

6.6.1 Profounda Corporation Information

6.6.2 Profounda Description and Business Overview

6.6.3 Profounda Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Profounda Cutaneous Leishmaniasis Drugs Product Portfolio

6.7.5 Profounda Recent Developments/Updates

6.8 Knight Therapeutics

6.8.1 Knight Therapeutics Corporation Information

6.8.2 Knight Therapeutics Description and Business Overview

6.8.3 Knight Therapeutics Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Knight Therapeutics Cutaneous Leishmaniasis Drugs Product Portfolio

6.8.5 Knight Therapeutics Recent Developments/Updates

6.9 Pfizer

6.9.1 Pfizer Corporation Information

6.9.2 Pfizer Description and Business Overview

6.9.3 Pfizer Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.9.4 Pfizer Cutaneous Leishmaniasis Drugs Product Portfolio

6.9.5 Pfizer Recent Developments/Updates

6.10 Xinhua Pharma

6.10.1 Xinhua Pharma Corporation Information

6.10.2 Xinhua Pharma Description and Business Overview

6.10.3 Xinhua Pharma Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Xinhua Pharma Cutaneous Leishmaniasis Drugs Product Portfolio

6.10.5 Xinhua Pharma Recent Developments/Updates

7 Cutaneous Leishmaniasis Drugs Manufacturing Cost Analysis

7.1 Cutaneous Leishmaniasis Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Cutaneous Leishmaniasis Drugs

7.4 Cutaneous Leishmaniasis Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Cutaneous Leishmaniasis Drugs Distributors List

8.3 Cutaneous Leishmaniasis Drugs Customers

9 Cutaneous Leishmaniasis Drugs Market Dynamics

9.1 Cutaneous Leishmaniasis Drugs Industry Trends

9.2 Cutaneous Leishmaniasis Drugs Market Drivers

9.3 Cutaneous Leishmaniasis Drugs Market Challenges

9.4 Cutaneous Leishmaniasis Drugs Market Restraints

10 Global Market Forecast

10.1 Cutaneous Leishmaniasis Drugs Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Cutaneous Leishmaniasis Drugs by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Cutaneous Leishmaniasis Drugs by Type (2023-2028)

10.2 Cutaneous Leishmaniasis Drugs Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Cutaneous Leishmaniasis Drugs by Application (2023-2028)

10.2.2 Global Forecasted Revenue of Cutaneous Leishmaniasis Drugs by Application (2023-2028)

10.3 Cutaneous Leishmaniasis Drugs Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Cutaneous Leishmaniasis Drugs by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Cutaneous Leishmaniasis Drugs by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer